Pacira Biosciences, Inc. has appointed Dr. Samit Hirawat to its board of directors, increasing the size of the company's board to 10 members. Dr. Hirawat brings more than 25 years of clinical development and industry expertise to the organization. He most recently served as the Chief Medical Officer, Executive Vice President, and Head of Global Drug Development at Bristol Myers Squibb, where he oversaw the worldwide clinical development portfolio and advanced multiple transformative therapies across therapeutic areas.
Pacira Biosciences is a leader in delivering innovative, non-opioid pain therapies, and currently has three commercial-stage non-opioid treatments: Exparel, Zilretta, and iovera. Exparel is a long-acting local analgesic currently approved for various pain management applications, while Zilretta is an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain, and iovera is a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The company is also advancing a pipeline of clinical-stage assets for musculoskeletal pain and adjacencies, with its most advanced product candidate being PCRX-201, a novel locally administered gene therapy in phase 2 clinical development for osteoarthritis of the knee.
Pacira's mission is to fundamentally transform how pain is treated for patients around the world, and the appointment of Dr. Hirawat is seen as pivotal during this time in the company's evolution. Dr. Hirawat's deep clinical development expertise and longstanding commitment to advancing innovative, patient-centric therapies are expected to make him an invaluable addition to the organization. The company looks forward to drawing on his insight and leadership as they accelerate the growth of their robust portfolio and pipeline of non-opioid pain solutions.
Dr. Hirawat's appointment to the board comes as the company continues to elevate the standard of care for patients and collaborate with a talented leadership team to further advance its mission. Today the company's shares have moved -7.21% to a price of $19.16. For the full picture, make sure to review Pacira BioSciences's 8-K report.
